Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it sued the regulator
Altria CEO Sal Mancuso has emphasized that responsibility must be a core focus in the company's FDA-regulated nicotine business. Speaking at the Fortune 500 Innovation Forum, Mancuso explained that competing in the FDA-regulated industry presents both a sense of responsibility to consumers and challenges in competing with other businesses in the space.
Altria's On! nicotine pouch brand, which is a key innovation for the company, has been impacted by regulations that have slowed its growth. The CEO stated that Altria's Moving Beyond Smoking initiative aims to lead the pouch category long-term. Mancuso highlighted that a significant challenge is the perception that nicotine causes harm, when it is primarily due to combustion.
He also mentioned that Altria, through its subsidiaries Helix Innovations and NJOY, recently sued the FDA, alleging that the agency has blocked newer nicotine products from reaching the market due to its review process, which takes longer than six months in some cases. This delay allows illicit products from foreign competitors to flood the market and circumvent FDA safety standards.
Mancuso believes regulations are currently broken and should be streamlined for a more rapid authorization process, ensuring a level playing field for responsible companies.
Written by urgent.news from Fortune's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.